The use of deep learning models to predict progression-free survival in patients with neuroendocrine tumors

被引:1
|
作者
Pavel, Marianne [1 ]
Dromain, Clarisse [2 ]
Ronot, Maxime [3 ]
Schaefer, Niklaus [2 ]
Mandair, Dalvinder [4 ]
Gueguen, Delphine [5 ]
Elvira, David [5 ]
Jegou, Simon [6 ]
Balazard, Felix [6 ]
Dehaene, Olivier [6 ]
Schutte, Kathryn [6 ]
机构
[1] Friedrich Alexander Univ Erlangen Nurnberg, Dept Med 1, Erlangen, Germany
[2] Lausanne Univ Hosp, Lausanne, Switzerland
[3] Beaujon Hosp, Clichy, France
[4] Royal Free Hosp, London, England
[5] Ipsen, Boulogne Billancourt, France
[6] Owkin, Paris, France
关键词
artificial intelligence; deep learning; neuroendocrine tumors; progression-free survival; RECIST; CONSENSUS GUIDELINES; CLINICAL UTILITY; CHROMOGRANIN-A; DIAGNOSIS; METASTASES; MANAGEMENT; RADIOMICS; RECIST;
D O I
10.2217/fon-2022-1136
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Plain language summary - The use of deep learning models to predict progression-free survival in patients with neuroendocrine tumorsNeuroendocrine tumors (NET) are slow-growing cancers. How well cancers respond to treatment is usually measured using 'Response Evaluation Criteria in Solid Tumors (RECIST)', which is based on measuring the size of tumors. RECIST is not well suited for assessing NETs as these tumors often grow slowly and rarely shrink significantly, so it is difficult to tell whether a treatment has any effect. A better way of measuring how well NETs are responding to treatment is needed, to ensure that patients receive the right treatment as early as possible.The RAISE project aimed to use a type of artificial intelligence (AI) called 'deep learning' to examine images of NETs, taken from patients in a clinical trial of treatment with lanreotide, to help predict how they might respond to treatment. These images were analyzed by the deep learning AI to see if there are any features of tumors, other than shape or size, that may help to predict response to treatment.The project showed that this technology can detect features in images of NETs, other than the shape and size of tumors, that are useful for predicting how well a treatment might work for an individual patient. However, this technology could not improve prediction of how well a treatment would work at an earlier stage compared with other currently used indicators.Overall, further research and work is needed to improve this technology. However, these results show that deep learning may have the potential to improve prediction of treatment response in patients with NETs. Aim: The RAISE project assessed whether deep learning could improve early progression-free survival (PFS) prediction in patients with neuroendocrine tumors. Patients & methods: Deep learning models extracted features from CT scans from patients in CLARINET (NCT00353496) (n = 138/204). A Cox model assessed PFS prediction when combining deep learning with the sum of longest diameter ratio (SLDr) and logarithmically transformed CgA concentration (logCgA), versus SLDr and logCgA alone. Results: Deep learning models extracted features other than lesion shape to predict PFS at week 72. No increase in performance was achieved with deep learning versus SLDr and logCgA models alone. Conclusion: Deep learning models extracted relevant features to predict PFS, but did not improve early prediction based on SLDr and logCgA.
引用
收藏
页码:2185 / 2199
页数:15
相关论文
共 50 条
  • [41] Development of a nomogram to predict progression-free survival in patients with locally advanced renal cell carcinoma
    Ruo-Tao Xiao
    Cheng Liu
    Bin Yang
    Wei He
    Chu-Xiao Xu
    Zhi-Gang Chen
    Lu-Lin Ma
    中华医学杂志英文版, 2021, 134 (22) : 2765 - 2767
  • [42] An MRI-based radiomics nomogram to predict progression-free survival in patients with endometrial cancer
    Liu, Ling
    Ji, Xiaodong
    Liang, Caihong
    Zhu, Jinxia
    Huang, Lixiang
    Zhao, Yujiao
    Xu, Xiangfeng
    Song, Zhiyi
    Shen, Wen
    FUTURE ONCOLOGY, 2024,
  • [43] Preoperative Tumor Growth Rate Does Not Predict Overall or Progression-free Survival in Patients With Glioblastoma
    Leppert, Jan
    Ditz, Claudia
    Matschke, Jakob
    Matone, Maria Vittoria
    Kuppler, Patrick
    Hillbricht, Christina
    Krenzlin, Harald
    Keric, Naureen
    Schacht, Hannes
    Ziemann, Christian
    Groh, Elisa Maria
    Liubich, Larysa
    Zemskova, Oksana
    Rades, Dirk
    Loeser, Anastassia
    ANTICANCER RESEARCH, 2024, 44 (11) : 5043 - 5049
  • [44] Levels of uninvolved immunoglobulins predict clinical status and progression-free survival for multiple myeloma patients
    Harutyunyan, Nika M.
    Vardanyan, Suzie
    Ghermezi, Michael
    Gottlieb, Jillian
    Berenson, Ariana
    Andreu-Vieyra, Claudia
    Berenson, James R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 174 (01) : 81 - 87
  • [45] Deep learning prediction of pathological complete response, residual cancer burden, and progression-free survival in breast cancer patients
    Dammu, Hongyi
    Ren, Thomas
    Duong, Tim Q.
    PLOS ONE, 2023, 18 (01):
  • [46] Association of progression-free survival with overall survival (OS) in patients (pts) with neuroendocrine tumor (NET) treated with somatostatin analogs
    Ter-Minassian, Monica
    Brooks, Nichole V.
    Brais, Lauren K.
    Chan, Jennifer A.
    Christiani, David C.
    Lin, Xihong
    Gabriel, Sylvie
    Dinet, Jerome
    Kulke, Matthew H.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [47] Predictive factors for overall and progression-free survival, and dissemination in oligodendroglial tumors
    Kanamori, Masayuki
    Kumabe, Toshihiro
    Sonoda, Yukihiko
    Nishino, Yoshikazu
    Watanabe, Mika
    Tominaga, Teiji
    JOURNAL OF NEURO-ONCOLOGY, 2009, 93 (02) : 219 - 228
  • [48] Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid Tumors
    Korn, Ronald L.
    Crowley, John J.
    CLINICAL CANCER RESEARCH, 2013, 19 (10) : 2607 - 2612
  • [49] Predictive factors for overall and progression-free survival, and dissemination in oligodendroglial tumors
    Masayuki Kanamori
    Toshihiro Kumabe
    Yukihiko Sonoda
    Yoshikazu Nishino
    Mika Watanabe
    Teiji Tominaga
    Journal of Neuro-Oncology, 2009, 93 : 219 - 228
  • [50] Development and Validation of Nomograms to Predict the Overall Survival and Progression-Free Survival in Patients with Advanced Unresectable Intrahepatic Cholangiocarcinoma
    Xian, Feng
    Song, Xuewu
    Bie, Jun
    Xu, Guohui
    CANCER MANAGEMENT AND RESEARCH, 2024, 16 : 1835 - 1849